Robert W. Baird Issues Positive Forecast for argenx (NASDAQ:ARGX) Stock Price

argenx (NASDAQ:ARGX) had its price target increased by Robert W. Baird from $650.00 to $680.00 in a research report released on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities analysts have also recently weighed in on ARGX. Wedbush reaffirmed an “outperform” rating and set a $655.00 price objective on shares of argenx in a research report on Tuesday, December 3rd. Wells Fargo & Company raised their price objective on shares of argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Oppenheimer lifted their price target on shares of argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Truist Financial reissued a “buy” rating and set a $700.00 price objective (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Finally, Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price on the stock in a report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $662.83.

argenx Price Performance

Shares of ARGX opened at $621.25 on Tuesday. The firm has a market capitalization of $37.75 billion, a PE ratio of -705.97 and a beta of 0.58. argenx has a 1-year low of $349.86 and a 1-year high of $678.21. The company’s fifty day moving average price is $642.51 and its 200-day moving average price is $591.91.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. As a group, research analysts anticipate that argenx will post 3.13 EPS for the current fiscal year.

Institutional Investors Weigh In On argenx

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC lifted its position in argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares during the period. Lord Abbett & CO. LLC acquired a new stake in shares of argenx in the 3rd quarter valued at approximately $88,339,000. Point72 Asset Management L.P. acquired a new stake in shares of argenx in the 4th quarter valued at approximately $91,013,000. Allspring Global Investments Holdings LLC lifted its holdings in argenx by 38,152.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after purchasing an additional 143,834 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in argenx by 184.7% during the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company’s stock valued at $117,805,000 after purchasing an additional 124,271 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.